3316F Er- or pr- breast cancer
Also known as: ER negative breast cancer, PR negative status, hormone receptor negative
Performance measure documenting estrogen receptor negative or progesterone receptor negative breast cancer. Quality metric for hormone receptor status determination.
In Plain Language
breast cancer that does not respond to hormone therapy
Clinical Context
Quality measure documenting hormone receptor negative status indicating need for chemotherapy or other systemic therapy rather than endocrine therapy alone.
RVU Information
CPT 3316F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.
Specialties
Frequently Asked Questions
What is CPT code 3316F?
CPT 3316F (Er- or pr- breast cancer) is a Other code. Performance measure documenting estrogen receptor negative or progesterone receptor negative breast cancer. Quality metric for hormone receptor status determination.
Who uses CPT code 3316F?
CPT 3316F is used by Oncology, Breast Surgery, Quality Reporting. Quality measure documenting hormone receptor negative status indicating need for chemotherapy or other systemic therapy rather than endocrine therapy alone.
When is CPT 3316F used?
Quality measure documenting hormone receptor negative status indicating need for chemotherapy or other systemic therapy rather than endocrine therapy alone.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.